Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.

Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean GR, Pichon S, Atkinson C, Milne RSB, Mach M, Griffiths PD, Reeves MB.

Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278. doi: 10.1073/pnas.1800224115. Epub 2018 Apr 23.

PMID:
29686064
2.

Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.

Baraniak I, Kropff B, McLean GR, Pichon S, Piras-Douce F, Milne RSB, Smith C, Mach M, Griffiths PD, Reeves MB.

J Infect Dis. 2018 May 25;217(12):1907-1917. doi: 10.1093/infdis/jiy102.

3.

Multispecificity of a recombinant anti-ras monoclonal antibody.

Schrader JW, McLean GR.

J Mol Recognit. 2018 Feb;31(2). doi: 10.1002/jmr.2683. Epub 2017 Nov 8.

PMID:
29115701
4.

The potential for a protective vaccine for rhinovirus infections.

Williams GR, Kubajewska I, Glanville N, Johnston SL, Mclean GR.

Expert Rev Vaccines. 2016 May;15(5):569-71. doi: 10.1586/14760584.2016.1142375. Epub 2016 Feb 15. No abstract available.

5.

Developing a vaccine for human rhinoviruses.

McLean GR.

J Vaccines Immun. 2014 Oct 1;2(3):16-20.

6.

Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.

Glanville N, McLean GR, Guy B, Lecouturier V, Berry C, Girerd Y, Gregoire C, Walton RP, Pearson RM, Kebadze T, Burdin N, Bartlett NW, Almond JW, Johnston SL.

PLoS Pathog. 2013;9(9):e1003669. doi: 10.1371/journal.ppat.1003669. Epub 2013 Sep 26.

7.

An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation.

Traub S, Nikonova A, Carruthers A, Dunmore R, Vousden KA, Gogsadze L, Hao W, Zhu Q, Bernard K, Zhu J, Dymond M, McLean GR, Walton RP, Glanville N, Humbles A, Khaitov M, Wells T, Kolbeck R, Leishman AJ, Sleeman MA, Bartlett NW, Johnston SL.

PLoS Pathog. 2013;9(8):e1003520. doi: 10.1371/journal.ppat.1003520. Epub 2013 Aug 1.

8.

Mice deficient in PAPP-A show resistance to the development of diabetic nephropathy.

Mader JR, Resch ZT, McLean GR, Mikkelsen JH, Oxvig C, Marler RJ, Conover CA.

J Endocrinol. 2013 Sep 6;219(1):51-8. doi: 10.1530/JOE-13-0167. Print 2013 Oct.

9.

The application of prophylactic antibodies for rhinovirus infections.

Privolizzi R, Solari R, Johnston SL, McLean GR.

Antivir Chem Chemother. 2014 Apr 11;23(5):173-7. doi: 10.3851/IMP2578. Review.

PMID:
23598287
10.

Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1.

McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, Gogsadze L, Niespodziana K, Valenta R, Bartlett NW, Johnston SL.

Antiviral Res. 2012 Sep;95(3):193-201. doi: 10.1016/j.antiviral.2012.06.006. Epub 2012 Jun 26. Erratum in: Antiviral Res. 2013 Mar;97(3):381. Peel, Tamlyn J [added].

PMID:
22742898
11.

Genetics and epidemiology: asthma and infection.

Bartlett NW, McLean GR, Chang YS, Johnston SL.

Curr Opin Allergy Clin Immunol. 2009 Oct;9(5):395-400. doi: 10.1097/ACI.0b013e32833066fa. Review.

PMID:
19644362
12.

Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus.

Thomson CA, Bryson S, McLean GR, Creagh AL, Pai EF, Schrader JW.

EMBO J. 2008 Oct 8;27(19):2592-602. doi: 10.1038/emboj.2008.179. Epub 2008 Sep 4.

13.

Where did the scientific method go?

Noseda M, McLean GR.

Nat Biotechnol. 2008 Jan;26(1):28-9. doi: 10.1038/nbt0108-28. No abstract available.

PMID:
18183010
14.

Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.

Schrader JW, McLean GR.

Immunol Lett. 2007 Sep 15;112(1):58-60. Epub 2007 Aug 6.

PMID:
17714794
15.

RIVETS: the recombinant immunoglobulin and viral epitope tag system.

McLean GR, Cho CW, Trotter B, Schrader JW.

J Immunol Methods. 2006 Aug 31;315(1-2):208-13. Epub 2006 Aug 2.

PMID:
16919678
16.

Autoreactivity of primary human immunoglobulins ancestral to hypermutated human antibodies that neutralize HCMV.

McLean GR, Cho CW, Schrader JW.

Mol Immunol. 2006 May;43(12):2012-22. Epub 2006 Jan 19.

PMID:
16423397
17.

The Steve Biko affair.

Jenkins T, McLean GR.

Lancet. 2004 Dec;364 Suppl 1:s36-7. No abstract available.

PMID:
15967146
18.

A point mutation in the Ch3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity.

McLean GR, Torres M, Trotter B, Noseda M, Bryson S, Pai EF, Schrader JW, Casadevall A.

Mol Immunol. 2005 May;42(9):1111-9. Epub 2005 Jan 4.

PMID:
15829300
19.

Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response.

McLean GR, Olsen OA, Watt IN, Rathanaswami P, Leslie KB, Babcook JS, Schrader JW.

J Immunol. 2005 Apr 15;174(8):4768-78.

20.

Biased immunoglobulin G (IgG) subclass production in a case of hyper-IgM syndrome.

McLean GR, Miller KK, Schrader JW, Junker AK.

Clin Diagn Lab Immunol. 2004 Nov;11(6):1192-3.

21.

The Steve Biko affair: a case study in medical ethics.

McLean GR, Jenkins T.

Dev World Bioeth. 2003 May;3(1):77-95.

PMID:
14577454
22.
23.

Specificity and diversity of antibodies to Mycobacterium tuberculosis arabinomannan.

Navoa JA, Laal S, Pirofski LA, McLean GR, Dai Z, Robbins JB, Schneerson R, Casadevall A, Glatman-Freedman A.

Clin Diagn Lab Immunol. 2003 Jan;10(1):88-94.

24.

Response of patients and families to lengthening of the facial bones by extraoral distraction osteogenesis: a review of 14 patients.

Ayoub AF, Duncan CM, McLean GR, Moos KF, Chibbaro PD.

Br J Oral Maxillofac Surg. 2002 Oct;40(5):397-405.

PMID:
12379186
25.

Isotype can affect the fine specificity of an antibody for a polysaccharide antigen.

McLean GR, Torres M, Elguezabal N, Nakouzi A, Casadevall A.

J Immunol. 2002 Aug 1;169(3):1379-86.

26.

Human and murine immunoglobulin expression vector cassettes.

McLean GR, Nakouzi A, Casadevall A, Green NS.

Mol Immunol. 2000 Oct;37(14):837-45.

PMID:
11257305
27.

Transcobalamin II and in vitro proliferation of leukemic cells.

McLean GR, Williams MJ, Woodhouse CS, Ziltener HJ.

Leuk Lymphoma. 1998 Jun;30(1-2):101-9.

PMID:
9669680
28.

Cobalamin analogues modulate the growth of leukemia cells in vitro.

McLean GR, Pathare PM, Wilbur DS, Morgan AC, Woodhouse CS, Schrader JW, Ziltener HJ.

Cancer Res. 1997 Sep 15;57(18):4015-22.

29.

A case for goodwill.

McLean GR.

BMJ. 1997 Mar 22;314(7084):890. No abstract available.

30.

Antibodies to transcobalamin II block in vitro proliferation of leukemic cells.

McLean GR, Quadros EV, Rothenberg SP, Morgan AC, Schrader JW, Ziltener HJ.

Blood. 1997 Jan 1;89(1):235-42.

31.

Thinking about the living will.

McLean GR.

S Afr Med J. 1995 Nov;85(11):1146-7. No abstract available.

PMID:
8597001
32.

HIV testing and informed consent--ethical considerations.

McLean GR, Jenkins T.

S Afr Med J. 1994 Oct;84(10):669-74.

PMID:
7839254

Supplemental Content

Loading ...
Support Center